Stockreport

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

Y-mAbs Therapeutics, Inc.  (YMAB) 
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm Check Earnings Report
PDF PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company fo [Read more]